Robbins Geller Rudman & Dowd LLP recently announced it is investigating potential violations of U.S. federal securities laws ...

LGND READ THE FULL LGND RESEARCH REPORT In the wake of the December analyst day, Ligand Pharmaceuticals, Inc.’s (NASDAQ:LGND) ...

This biopharma firm targets rare diseases with both approved therapies and a pipeline of clinical-stage treatments.

Lulu’s Fashion Lounge Holdings Inc (NASDAQ: LVLU) shares dipped 10.4% to $10.89 in pre-market trading. Lulu’s Fashion Lounge Holdings shares jumped 79% on Monday after Friedland Enterprises acquired a ...

Travere Therapeutics recently reported that the FDA has extended its review of the supplemental New Drug Application for FILSPARI (sparsentan) in focal segmental glomerulosclerosis (FSGS) to a new ...

Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best mid-cap growth stocks to buy right now. On January 14, Bank of America lowered its price target on Travere Therapeutics to $43 from $47, ...

The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving Travere Therapeutics, Inc.

The FDA has extended its review of the company's Filspari. This is a setback for the biotech's leading drug candidate. Travere's leading drug candidate is Filspari, which targets a kidney disorder ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a ...

Travere Therapeutics, Inc., (Nasdaq: TVTX) announced that today the U.S. Food and Drug Administration (FDA) has extended the review timeline of its supplemental New Drug Application (sNDA) for ...